menu
    • menu
    [{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"BC-3781","moa":"antibacterials","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nabriva Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nabriva Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aerogen","sponsor":"Ohio State University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Epoprostenol Sodium","moa":"Prostanoid IP receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aerogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aerogen \/ Ohio State University","highestDevelopmentStatusID":"8","companyTruncated":"Aerogen \/ Ohio State University"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Orbsen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Orbsen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orbsen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Orbsen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Icon Plc","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Icon Plc \/ BARDA"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Chris Miller","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gas for Inhalation","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Chris Miller","highestDevelopmentStatusID":"8","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Chris Miller"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Icon Plc

                            Ireland arrow
                            Tides Europe
                            Not Confirmed

                            Icon Plc

                            Ireland arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : BARDA

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            BARDA Partners with ICON to Execute Next Generation COVID-19 Vaccines Clinical Trial

                            Details : The partnership aims to execute a Phase 2b clinical trial to assess the relative efficacy of a next generation COVID-19 vaccine compared to currently approved/authorised COVID-19 vaccines in the prevention of symptomatic, PCR confirmed SARS-CoV-2 infecti...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 13, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : BARDA

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Mallinckrodt Pharmaceuticals

                            Ireland arrow
                            Tides Europe
                            Not Confirmed

                            Mallinckrodt Pharmaceuticals

                            Ireland arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitric Oxide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mallinckrodt Initiates Retrospective Study of the Use of Inhaled Nitric Oxide in COVID-19 Patients

                            Details : Mallinckrodt has initiated a retrospective chart review study, titled "Nitric Oxide Treatment In COVID-19 Evaluation (NOTICE)" to collect real-world data on the use of INOmax® gas, for inhalation therapy in patients with respiratory complications associ...

                            Product Name : INOmax

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 10, 2020

                            Lead Product(s) : Nitric Oxide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aerogen

                            Ireland arrow
                            Tides Europe
                            Not Confirmed

                            Aerogen

                            Ireland arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epoprostenol Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Ohio State University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation

                            Details : Epoprostenol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 30, 2020

                            Lead Product(s) : Epoprostenol Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Ohio State University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Orbsen Therapeutics

                            Ireland arrow
                            Tides Europe
                            Not Confirmed

                            Orbsen Therapeutics

                            Ireland arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic Umbilical Cord Mesenchymal Stem Cell

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Multiverse Investment Fund Announces Portfolio Company’s Commencement of Clinical Trials to Treat ARDS Cause...

                            Details : Orbsen Therapeutics’ proprietary ORBCEL cellular therapy demonstrated the ability to mitigate the effects of ARDS by improving lung oxygenation.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            April 15, 2020

                            Lead Product(s) : Allogeneic Umbilical Cord Mesenchymal Stem Cell

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Mallinckrodt Pharmaceuticals

                            Ireland arrow
                            Tides Europe
                            Not Confirmed

                            Mallinckrodt Pharmaceuticals

                            Ireland arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitric Oxide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Chris Miller

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) In...

                            Details : Nitric Oxide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Respiratory Tract Infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 06, 2017

                            Lead Product(s) : Nitric Oxide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Chris Miller

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Nabriva Therapeutics

                            Ireland arrow
                            Tides Europe
                            Not Confirmed

                            Nabriva Therapeutics

                            Ireland arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BC-3781

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial...

                            Details : BC-3781 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Bacterial Infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 07, 2010

                            Lead Product(s) : BC-3781

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth